Literature DB >> 15375522

Prognostic value of Topoisomerase II in female breast cancer.

Rumelia Koren1, Lea Rath-Wolfson, Edward Ram, Ofer Ben Itzhac, Benny Schachter, Baruch Klein, Rivka Gal, Zeev Dreznik.   

Abstract

Topoisomerase II-alpha (Topo II-alpha) is a nuclear enzyme. Its expression rises rapidly at the end of the S to G2/M phase and falls after the mitotic process ends. We have studied the immunohistochemical expression of Topo II-alpha in breast cancer and its correlation with the menopausal state, tumor type, size, lymph node metastases, stage, and estrogen and progesterone positivity. Histological sections from 50 breast cancers were immunohistochemically stained for Topo II-alpha. The percent of positive cells at the area of highest staining was recorded as Topo index. The correlation between the course of disease, survival and Topo II-alpha index was statistically significant, p<0.001. High-grade tumors showed higher Topo II-alpha levels, than those of intermediate and low-grade, p<0.01. A significant association was found between estrogen receptors positivity and Topo II-alpha, p<0.05. A higher Topo II-alpha index indicates higher probability for recurrence of the disease and overall survival. Therefore, Topo II-alpha expression has a prognostic value in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375522

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A.

Authors:  Alexandre E Escargueil; Annette K Larsen
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

2.  Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.

Authors:  Mehmet Salih Iyikesici; Gul Basaran; Faysal Dane; Meltem Ekenel; P Fulden Yumuk; Devrim Cabuk; Mehmet Teomete; N Serdar Turhal
Journal:  Int J Clin Exp Med       Date:  2014-05-15

3.  A comparative analysis of gene-expression data of multiple cancer types.

Authors:  Kun Xu; Juan Cui; Victor Olman; Qing Yang; David Puett; Ying Xu
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

4.  Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.

Authors:  K Talvinen; J Tuikkala; O Nevalainen; A Rantanen; P Hirsimäki; J Sundström; P Kronqvist
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640

5.  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.

Authors:  George Fountzilas; Christos Christodoulou; Mattheos Bobos; Vassiliki Kotoula; Anastasia G Eleftheraki; Ioannis Xanthakis; Anna Batistatou; George Pentheroudakis; Nikolaos Xiros; Irene Papaspirou; Anna Koumarianou; Pavlos Papakostas; Dimitrios Bafaloukos; Dimosthenis V Skarlos; Konstantine T Kalogeras
Journal:  J Transl Med       Date:  2012-10-23       Impact factor: 5.531

6.  A novel five gene signature derived from stem-like side population cells predicts overall and recurrence-free survival in NSCLC.

Authors:  Deepak Perumal; Sandeep Singh; Sean J Yoder; Gregory C Bloom; Srikumar P Chellappan
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

7.  Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp.

Authors:  Tuvia Hadar; Jacob Shvero; Eitan Yaniv; Itzhac Shvili; Mircea Leabu; Rumelia Koren
Journal:  J Cell Mol Med       Date:  2008-06-09       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.